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Background: Reticular basement membrane (RBM) thickening has been variably associated 
with asthma and chronic obstructive pulmonary disease (COPD). Even if RBM thickness is 
similar in both diseases, its composition might still differ.
Objective: To assess whether RBM thickness and composition differ between asthma and COPD.
Methods: We investigated 24 allergic asthmatics (forced expiratory volume in one second 
[FEV1] 92% predicted), and 17 nonallergic COPD patients (FEV1 60% predicted), and for each 
group a control group of similar age and smoking habits (12 and 10 persons, respectively). Snap-
frozen sections of bronchial biopsies were stained with hematoxylin/eosin and for collagen I, III, 
IV, V, laminin and tenascin. RBM thickening was assessed by digital image analysis. Relative 
staining intensity of each matrix component was determined.
Results: Mean (SD) RBM thickness was not signiﬁ  cantly different between asthma and COPD 
5.5 (1.3) vs 6.0 (1.8) μm, but signiﬁ  cantly larger than in their healthy counterparts, ie, 4.7 (0.9) 
and 4.8 (1.2) μm, respectively. Collagen I and laminin stained signiﬁ  cantly stronger in asthma 
than in COPD. Tenascin stained stronger in asthma than in healthy controls of similar age, and 
stronger in COPD controls than in asthma controls (p   0.05).
Conclusion: RBM thickening occurs both in asthma and COPD. We provide supportive evidence 
that its composition differs in asthma and COPD.
Keywords: reticular basement membrane thickness, reticular basement membrane composition, 
asthma, biopsy, COPD, remodeling
Introduction
One of the hallmarks of airway remodeling is a thickened airway reticular basement 
membrane (RBM) as a result of extracellular matrix deposition directly apposing 
the lamina reticularis.1,2 In an earlier study, Kasahara and colleagues compared the 
thickness of the RBM (biopsies) and of the whole airway wall thickness as assessed 
by high-resolution computed tomography (HRCT) in patients with mild-to-moderate 
asthma and healthy controls matched for age and sex.3 They showed that RBM 
thickness in asthmatic patients was larger than that of healthy controls and that it 
correlated strongly with whole airway wall thickness and forced expiratory volume 
in one second (FEV1). Furthermore, James and colleagues showed similar ﬁ  ndings 
comparing the reticular basement membrane thickness of central airways assessed 
by endobronchial biopsy and airway wall dimensions in cartilaginous airways in 
surgical specimens.4 Although disputed by others,5 these ﬁ  ndings support earlier 
studies suggesting that RBM thickness may be used as an index of remodeling of the 
airway wall in asthma.
In contrast to asthma, the literature is not unanimous whether airway RBM is 
thickened in patients with chronic obstructive pulmonary disease (COPD). Some 
studies ﬁ  nd a normal RBM,6–8 while others report it to be thickened,9–13 but generally International Journal of COPD 2009:4 128
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to a smaller extent than in asthma.9,10,12,14,15 The differences 
in observations may be due to the fact that some studies have 
included only a few COPD patients7 or COPD patients with 
only mild10 or more severe9 airway obstruction. In addition, 
some studies included healthy controls who were either never 
smokers11 or smokers not being matched for pack-years 
smoking.8 Airway inﬂ  ammation is of a chronic nature in both 
asthma and COPD, likely resulting in a long-lasting increase 
of ﬁ  brogenic growth factors like transforming growth factor-
β in both asthma and COPD,10,16 vascular endothelial growth 
factor in asthma,17 and epidermal growth factors in COPD.10 
Thus it might be anticipated that the RBM is thickened in 
both asthma and COPD.
Collagen IV, laminin, and proteoglycans are the major 
components of the true basement membrane. Beneath this 
thin layer, collagen I, III, V, and tenascin amongst others 
form the lamina reticularis, which is thickened in asthma 
patients. Both layers are strongly connected by strands of 
collagen VII. Laminin and tenascin have binding sites for 
the other matrix proteins, as well as for mesenchymal and 
epithelial cells. Together with proteoglycans, these matrix 
proteins form a ﬁ  rm and complex network that regulates 
processes like cell-migration and cell-adhesion.
We hypothesized that extracellular matrix deposition, 
resulting in RBM thickening, occurs in both asthma and 
COPD. Since the inflammatory profile differs between 
asthma and COPD, we anticipated that the extracellular 
matrix composition of RBM differs in terms of the relative 
contribution of each ECM component. We analyzed bron-
chial biopsies of patients with asthma and COPD with respect 
to the relationship between RBM thickness and composition 
on one hand, and FEV1, bronchial hyperresponsiveness on the 
other hand. Because the RBM thickness and composition may 
change during aging, we compared each group with age- and 
pack-years smoking-matched healthy controls.
Methods
Subjects
Subjects were recruited from our outpatient clinic of the 
University Medical Center Groningen or by advertisements 
in local newspapers. The local medical ethics committee 
approved the protocols and all subjects gave their written 
informed consent.
Asthma patients and healthy controls
Twenty-four subjects with mild-to-moderate severe asthma, 
18–45 years old, were included. Their results of inﬂ  amma-
tory composition of airway wall biopsies have been reported 
previously.18 Asthmatics were selected on: history consistent 
with asthma; positive intracutaneous tests against house dust 
mite or two other aeroallergens (18 common aeroallergens of 
ALK, Groningen, the Netherlands), FEV1   60% predicted; 
provocative concentration of methacholine causing a 20% 
fall in FEV1 (PC20methacholine)  9.8 mg/ml; and provoca-
tive concentration of adenosine-5-monophosphate (AMP) 
causing a 20% fall in FEV1 (PC20AMP)  80 mg/ml. Twelve 
healthy volunteers of similar age were selected on: no his-
tory of lung disease; FEV1   85% predicted, no atopy and 
no airways hyperresponsiveness to methacholine or AMP. 
Asthmatic and healthy subjects who had been smoking in 
the past two years were excluded.
COPD patients and healthy controls
Seventeen COPD subjects over 45 years of age were 
included, according to American Thoracic Society (ATS) 
criteria.19 All subjects had a negative history of atopy, 
negative skin tests to 18 common aeroallergens (ALK, 
Groningen, the Netherlands) and negative speciﬁ  c IgE for 
11 common aeroallergens (phadiatop®). Subjects with COPD 
had an FEV1 and FEV1/vital capacity (VC)  predicted 
value −1.64 residual standard deviations20 and an increase in 
FEV1   10% predicted after inhalation of 1 mg terbutaline 
per Turbuhaler®. Three subjects were never-smokers, all 
other participants were ex-smokers, ie they quitted smoking 
at least one year before the start of the study. Ten healthy 
ex-smoking volunteers were included without a history of 
pulmonary disease, with normal lung function, and similar 
age and pack-years smoking.
All patients stopped inhaled corticosteroids at least four 
weeks prior to bronchoscopy. Exclusion criteria were treat-
ment with oral prednisolone and/or antibiotics, or a respira-
tory infection within four weeks prior to the study. Because 
of safety reasons, all patients had an FEV1   1.5 L.
Lung function
FEV1 was performed according to standardized guidelines 
of the European Respiratory Society.20 Reversibility was 
tested 30 minutes after inhalation with 400 μg salbutamol in 
asthma and with 1 mg terbutaline in COPD. Subjects were not 
allowed to use short-acting bronchodilators within 12 hours 
or long-acting bronchodilators within 24 hours.
Bronchoscopy and processing of biopsies
Bronchoscopy was performed using an Olympus B1 IT10 ﬂ  ex-
ible ﬁ  beroptic bronchoscope (Olympus Optical, Tokyo, Japan) 
according to American Thoracic Society (ATS) criteria.21 International Journal of COPD 2009:4 129
RBM thickness and composition in asthma and COPD
At least ﬁ  ve biopsies were taken from the subsegmental carinas 
from the left or right lower lobe using a fenestrated cup forceps 
(Olympus BF-21-C, Tokyo Japan).
Biopsies were mounted in Tissue Tek® embedding com-
pound and snap-frozen by immersion in isopentane (−80 °C). 
Frozen biopsies were cut in serial sections at 4-μm thickness. 
Selection of morphologically optimal tissue was based on 
every twentieth section, stained with Mayer’s hematoxylin 
and eosin. Slides were stored at −20 °C.
Measuring of reticular basement 
membrane thickness
Sections from all biopsies from each patient were stained 
with Mayer’s hematoxylin and eosin. The morphologically 
most optimal section was selected by including sections with 
optimal integrity of the RBM and excluding tangentially 
cut tissue. RBM thickness was assessed by digital analysis 
(Leica Quantimed, Zeist, The Netherlands). Sections were 
coded and measured in random order at a magniﬁ  cation of 
400x. One technician (MZ) performed all measurements. 
Fifteen measurements were performed over a cumulative 
length of basement membrane of 750 μm in each section. 
These measurements were equally distributed over the total 
length of the basement membrane. For each measurement, 
an area of the RBM was marked over a length of 50 μm. 
Thereafter, the exact surface area of basement membrane 
and apposed matrix was assessed. Dividing the surface 
(calculated by the computer) by its exact length resulted in 
the mean RBM thickness of the marked surface area. The 
mean RBM thickness of an individual section was the mean 
of 15 measurements.
Immunostaining
Immunohistochemical staining was performed on 4 μm 
sections of snap-frozen biopsies, dried at room temperature 
and ﬁ  xed for 10 minutes in acetone. Slides were rinsed three 
times in phosphate-buffered saline (PBS) for ﬁ  ve minutes 
between each step. Sections were stained for collagen I (goat 
polyclonal antibody; Southern Biotechnology Associates, 
Birmingham, AL, USA, see Figure 3), collagen III (mouse 
monoclonal antibody; Heyl, Berlin, Germany), collagen 
IV (rabbit polyclonal antibody; Cappel/ICN, Aurora, OH, 
USA), collagen V (goat polyclonal antibody; Southern Bio-
technology Associates, Birmingham, AL, USA), laminin 
(rabbit polyclonal antibody; Telios, San Diego, CA, USA), 
and tenascin (mouse monoclonal antibody; Telios). Subse-
quently, the sections were put in PBS with 0.075% H2O2 for 
30 minutes to block endogenous peroxidase activity. Finally, 
sections were treated with species-specific peroxidase-
conjugated immunoglobulins (DAKO; Glostrup, Denmark) 
for 30 minutes and peroxidase staining was performed using 
3-amino-ethylcarbazole (AEC; Sigma Chemical Company, 
St. Louis, MO, USA) as a substrate, providing a reddish-
brown reaction product.
Examination of (reticular) basement 
membrane components
Semi-quantitative examination was performed by one 
investigator (MZ) in a blinded fashion using a light 
microscope at 100x magniﬁ  cation. Before semi-quantitative 
scoring of individual sections, all sections immuno-stained 
for a speciﬁ  c antigen were examined in order to have an 
impression of the range of immunopositivity. Thereafter, 
sections were scored on a three-point scale for staining 
intensity of the reticular basement membrane (1, low; 2, 
moderate; 3, high intensity). Intra-observer agreements 
(kappa, standard error) for collagen I, III, IV, V, laminin, 
and tenascin were: 0.74 (0.14), 0.81 (0.13), 0.80 (0.13), 0.51 
(0.19), 0.84 (0.11), and 0.73 (0.14), respectively.
Data analysis
Analyses were performed with the SPSS (version 10.0; SPSS 
Inc., Chicago, IL, USA) software package. Normality of dis-
tribution was assessed with the Kolmogorov–Smirnov test. 
Differences in RBM thickness were evaluated by ANOVA 
followed by t-test, differences in staining activity of matrix 
components by Mann–Whitney U Test. Correlations between 
RBM thickness and FEV1 were evaluated by Pearson tests, 
correlations between RBM thickness and composition on the 
one hand, and PC20AMP on the other hand with Spearman 
tests. P-values   0.05 were considered to be signiﬁ  cant.
Results
Subjects
Clinical characteristics of the patients with asthma and 
COPD, and their healthy controls are listed in Table 1. After 
analyzing RBM thickness, two subjects with asthma and one 
subject with COPD did not yield sufﬁ  cient tissue to evaluate 
the RBM composition.
Reticular basement membrane thickness
Values of the RBM thickness showed a normal distribution 
in all groups. The variability in RBM thickness was not 
signiﬁ  cantly different between asthma and COPD. Mean 
(standard deviation) RBM thickness in asthma and COPD 
was signiﬁ  cantly greater than that of healthy controls of International Journal of COPD 2009:4 130
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similar age: 5.5 (1.3) μm vs 4.7 (0.9) μm in asthma, and 6.0 
(1.8) vs 4.8 (1.2) μm in COPD (Figure 1).
Composition of the reticular basement 
membrane
Assessment of the RBM staining with collagen I, III, IV, V, 
tenascin, and laminin showed that collagen I (Figure 3) and 
laminin staining of the RBM were signiﬁ  cantly more intense 
in asthma than in COPD (p   0.05, Figure 2). In contrast, 
collagen IV showed a trend towards more intense staining 
in COPD than in asthma (p = 0.084, Figure 2). Tenascin 
staining of the RBM was signiﬁ  cantly more intense in asth-
matics than in healthy controls (p   0.05, Figure 2), but not 
signiﬁ  cantly different from COPD. Tenascin staining was 
signiﬁ  cantly more intense in the COPD than in the asthma 
control group (Figure 2). No further signiﬁ  cant differences 
were found between the four study groups.
Correlations of basement membrane 
and clinical characteristics
There were no signiﬁ  cant correlations between RBM thick-
ness or extracellular matrix components (Collagen I, III, 
IV, V, tenascin, and laminin) on one hand and FEV1% pred, 
PC20AMP, and PC20methacholine (in asthma only) on the 
other hand, neither in asthmatics, nor in COPD patients, nor 
in healthy subjects.
Discussion
This study shows that the reticular airway basement membrane 
is thickened both in patients with mild-to-moderate asthma 
and COPD, as compared to healthy subjects of similar age 
and smoking history. An interesting observation is that the 
extracellular matrix composition of the reticular basement 
membrane differs between asthma and COPD, the latter 
containing signiﬁ  cantly less collagen I and laminin. The 
reticular basement membrane thickness and its extracellular 
matrix composition did not significantly correlate with 
parameters of lung function.
To our knowledge this is the ﬁ  rst study comparing RBM 
thickness in asthma and COPD patients and their healthy 
controls of similar age and smoking history. An important 
ﬁ  nding of this study is that the airway RBM in central airway 
biopsies is thickened with a similar magnitude in asthma and 
COPD. Other reports give contrasting results.7,9,10,12,14,15,22 
There are several explanations for this difference. Two studies 
compared asthma patients with a mixed group of COPD and 
chronic bronchitis patients (thus individuals with and without 
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Figure 1 Mean basement membrane thickness for asthma, COPD, and healthy controls 
of similar age. Reticular basement membrane thickness in central airway wall biopsies 
from 24 patients with asthma, 12 age-matched healthy controls of asthma, 17 patients 
with COPD and 10 age- and pack year-matched healthy controls of COPD.
Notes: Solid lines are means; *p   0.05.
Abbreviation: COPD, chronic obstructive pulmonary disease.
Table 1 Baseline characteristics
Asthma Asthma controls COPD COPD controls
Numbers 24 12 17 10
Gender, M/F 15/9 4/8 13/4 8/2
Age, years 31 (9.1) 31 (8.2) 62 (7.5) 59 (7.8)
FEV1, % pred 92 (12.6) 105 (13.8) 60 (13.0) 105 (10.5)
Reversibility, FEV1 % pred 11.5 (9.7) 1.6 (2.2) 5.4 (2.5) 3.0 (3.2)
Pack years – – 27.8 (21.0) 25.8 (15.1)
Current smoking 0 0 0 0
PC20AMP, mg/ml 2.5 (0.18–22.8)  80 121 (1–267)  80
PC20methacholine, mg/ml 0.42 (0.8–6.61)  9.8 Not done Not done
Note: Data are presented in mean (standard deviation) or median (range).
Abbreviations: FEV1, forced expiratory volume in the ﬁ  rst second;   AMP, adenosine-5’-monophosphate; PC20, provocative concentration causing a 20% fall in FEV1.International Journal of COPD 2009:4 131
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status.1,5,7,9–13,15,17,22,24–44 Taken together, we conclude that an 
increased RBM thickness indicates the presence of asthma 
or COPD, irrespective of age and that it is not possible to 
differentiate mild-to-moderate asthma from COPD purely 
based on RBM thickness. In addition, a normal RBM thickness 
does not exclude obstructive airway disease.
One could postulate that the age difference between our 
asthma and COPD patients, or asthma severity is responsible 
for the lack of difference in RBM thickness. Earlier studies 
have shown that RBM thickness is not associated with 
asthma duration,25,26,45–47 age,20,27 or asthma severity.12,26,27 
Notwithstanding this, Bourdin and colleagues recently 
provided evidence that particularly patients with severe 
asthma have a larger thickness of the RBM than asthmatics 
with mild disease. The latter two groups had similar duration 
of disease, conﬁ  rming that it is not duration but rather severity 
of disease that affects RBM thickness. Our data for the ﬁ  rst 
time show that age and aging may not affect RBM thickness, 
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Figure 2 Reticular basement membrane composition. Relative staining density of collagen I, laminin, collagen IV, and tenascin in the reticular basement membrane of airway 
wall biopsies in asthma and COPD patients, and their healthy matched control subject. Results of collagen III and V are not shown as there were no signiﬁ  cant differences 
between any of the groups.
Notes: *p   0.05, #p = 0.08.
Abbreviation: COPD, chronic obstructive pulmonary disease.
airway obstruction) ﬁ  nding a thicker RBM in asthma than 
in the mixed group.10,22 Two other studies reported a thicker 
RBM in asthma than in COPD,7,9 however these studies did 
not report their data in a quantitative way. Our study has the 
advantage that a more homogeneous group of COPD patients 
was selected, and additionally that RBM was measured using 
a computerized morphometry system, providing quantitative 
and non-selective data. In line with our results, Bourdin and 
colleagues demonstrated RBM thickness of a comparable mag-
nitude as our ﬁ  ndings in (mild) asthma and COPD and reported 
that this is not a useful histological marker to differentiate 
between these diseases.13,23 In the latter study, a measurement 
method similar to ours was used which has been validated by 
Wilson and colleagues.24 We also demonstrate that the mean 
SBM thickness in asthma and COPD patients is larger than in 
healthy controls, though with a large overlap. This overlap is 
in line with earlier studies, despite the use of different methods 
and use of healthy controls with different age and/or smoking International Journal of COPD 2009:4 132
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A)
B)
Figure 3 Collagen I staining. Immunohistochemical staining of bronchial biopsies for collagen I (immunoperoxidase, original magniﬁ  cation × 200) showed, a uniform 
red-brown-stained band beneath the epithelial layer in asthma (A left panel). In contrast to asthma, this is signiﬁ  cantly less intense in COPD (p   0.05, B right panel).
Abbreviation: COPD, chronic obstructive pulmonary disease.International Journal of COPD 2009:4 133
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but they do affect the composition of the RBM, since tenascin 
was signiﬁ  cantly more present in COPD controls than in 
the asthma control group, which by design of the study 
was younger in age. Alternatively, this may be the result of 
long-time smoke exposure, because COPD controls were 
ex-smokers and asthma controls were never-smokers.
The mean RBM thickness in our study is somewhat 
smaller in both asthma and COPD than in most other studies. 
This can be the result of using snap-frozen biopsies instead 
of embedding biopsies in resin or parafﬁ  n, or differences in 
ﬁ  xation techniques. The manner of measuring RBM thickness 
is to our opinion decisive for the observed differences. 
First, we used area measurements, which Bourdin and 
colleagues showed to result in lower values than when 
using line measurements.13 By using area measurements, 
we evaluated a signiﬁ  cantly larger part of the RBM to assess 
thickness; for example we used 15 areas of 50 μm length 
while Sullivan used 40 line measurements.48 Second, we 
measured completely random, large areas of RBM, while 
line measurements are more prone to selection bias. Thus our 
method has advantage over previous publications in that we 
used a more unbiased measuring method.12,14,15
This study is the ﬁ  rst to demonstrate that the extracellular 
matrix composition of the RBM differs between asthma and 
COPD, yet with large overlap in staining pattern. Previous 
studies have used staining of different collagens, but did 
not asses its further composition.24,30,33–36,40 The observed 
differences between asthma and COPD in the extracellular 
matrix composition may be due to different types of 
irritation, epithelial damage, epithelial repair, and underlying 
submucosal airway inﬂ  ammation, both in a quantitative and 
qualitative way. Collagen IV is a component of the “true” 
basement membrane which is not thickened in asthma. 
Compared to asthma, collagen IV showed a trend for a higher 
staining intensity in COPD.
The above differences in composition underline 
differences in pathophysiology of both diseases. Tenascin 
stained stronger in asthma than in healthy controls of 
similar age and also stronger in (older) COPD controls than 
in (younger) asthma controls. Kranenburg and colleagues 
compared the staining intensity of the RBM in patients with 
COPD and healthy subjects in surgical resection specimens 
using a similar scoring system as in our study.49 Their results 
showed enhanced expression of total collagen, collagen I, 
and –III, but not of collagen IV, ﬁ  bronectin, and laminin. 
Differences with our ﬁ  ndings are likely caused by the use of 
surgical resection specimens whereas we investigated large 
airway bronchoscopic biopsies.
A thickened RBM and a change in its composition are 
both features of airway remodelling, which is supposed to 
contribute to airﬂ  ow limitation in asthma and COPD. This 
study shows no signiﬁ  cant correlations of RBM thickness 
and composition with FEV1% predicted, in line with 
some25,30,47 but not all studies.13,18,27,34 Obviously, different 
results may be explained by differences in study populations 
and morphometric methods. Furthermore, we could not 
demonstrate a signiﬁ  cant correlation between PC20AMP 
and RBM thickness. With respect to PC20methacholine 
several other studies have shown a negative correlation 
with RBM thickness in asthma.25,29,34,50 This would suggest 
that PC20methacholine is more closely related to markers 
of airway remodeling than PC20AMP, yet our data did not 
conﬁ  rm this. Whether a thickened basement membrane is 
beneﬁ  cial or harmful for the natural course of asthma or 
COPD, eg, by protecting against allergen or smoke exposure, 
is not supported by long-term follow-up studies.
In summary, this study shows that the reticular basement 
membrane is thickened in both asthma and COPD, yet has a 
different composition. More studies are needed to elucidate 
the exact relationship between the process of ongoing airway 
inﬂ  ammation and airway remodeling in these diseases.
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